TYRA
Tyra Biosciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
26.05
▲ 0.36 (1.40%)
MARKET · —
Price
Open
25.44
Prev close
25.69
Day high
26.81
Day low
25.95
Volume
334.95K
Market cap
$1.55B
P/E (TTM)
—
52W range
11.70 – 40.65
Trailing performance
Returnvs SPY
1W
+3.01%
+4.4%
1M
-15.42%
-19.2%
3M
-21.11%
-24.2%
6M
-17.51%
-28.6%
YTD
-0.91%
-13.2%
1Y
+154.39%
+134.4%
3Y
+74.95%
+0.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.55B
Enterprise value$1.21B
Revenue (TTM)—
Gross profit—
EBITDA$-159.92M
Net income$-148.56M
EPS (TTM)$-2.39
Free cash flow$-63.07M
Total cash$353.94M
Total debt$5.58M
Book value / share$4.83
Shares outstanding59.68M
Float35.21M
Short % of float28.56%
Dividend yield—
Beta (5Y)0.77
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.79
PEG ratio—
Price / sales—
Price / book5.40
EV / revenue—
EV / EBITDA-7.54
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-45.31%
Return on assets-28.46%
Debt / equity1.58
Current ratio14.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.64 | -0.69 | -7.0% |
| Mar 2026 | -0.59 | -0.64 | -8.6% |
| Dec 2025 | -0.53 | -0.57 | -8.5% |
| Sep 2025 | -0.51 | -0.50 | +2.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.68 | 14 | $0 | 0.0% |
| Next quarter | -0.71 | 14 | $0 | 0.0% |
| Current year | -2.67 | 14 | $0 | 0.0% |
| Next year | -2.96 | 14 | $0 | 0.0% |
Analyst targets & ownership
Mean target$50.82
High target$59.00
Low target$39.00
Implied upside95.08%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy2 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders2.85%
Held by institutions117.45%
Institutions holding241
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+203.36K
Net buying
Buy transactions
8
217.65K shares
Sell transactions
1
14.29K shares
Net transactions
+9
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
1.70M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 5, 26 | HARRIS TODD JAMES Chief Executive Officer |
STOCK | 79.00K | $0 | Direct |
| May 5, 26 | FUHRMAN ALAN CPA Chief Financial Officer |
STOCK | 20.00K | $0 | Direct |
| May 5, 26 | ASHAR BHAVESH Chief Operating Officer |
STOCK | 15.01K | $0 | Direct |
| May 5, 26 | WARNER DOUGLAS J Officer |
STOCK | 25.00K | $0 | Direct |
| May 5, 26 | RUEB YULIYA Officer |
STOCK | 8.33K | $0 | Direct |
| Mar 26, 26 | KAPLAN GILLA Director |
CONVERSION | 67.47K | $151.80K | Direct |
| Mar 25, 26 | KAPLAN GILLA Director |
SELL | 14.29K | $528.51K | Direct |
| Mar 13, 26 | HARRIS TODD JAMES Chief Executive Officer |
STOCK | 1.46K | $52.99K | Direct |
| Mar 13, 26 | FUHRMAN ALAN CPA Chief Financial Officer |
STOCK | 1.38K | $49.84K | Direct |
| Feb 12, 26 | BENSEN DANIEL Officer |
SELL | 8.00K | $262.96K | Direct |
| Jan 12, 26 | BENSEN DANIEL Officer |
SELL | 8.00K | $228.19K | Direct |
| Dec 19, 25 | MORE ROBERT J Director |
SELL | 10.00K | $250.00K | Indirect |
| Dec 12, 25 | BENSEN DANIEL Officer |
SELL | 8.00K | $181.16K | Direct |
| Nov 21, 25 | MORE ROBERT J Director |
SELL | 246.87K | $5.00M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ASHAR BHAVESH |
Chief Operating Officer | 15.01K | Stock Award(Grant) |
BENSEN DANIEL |
Officer | 146.98K | Sale |
FUHRMAN ALAN CPA |
Chief Financial Officer | 36.16K | Stock Award(Grant) |
HARRIS TODD JAMES |
Chief Executive Officer | 1.44M | Stock Award(Grant) |
KAPLAN GILLA |
Director | 28.23K | Conversion of Exercise of derivative security |
KJELLSON NINA S |
Director | — | Sale |
MORE ROBERT J |
Director | — | Sale |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RUEB YULIYA |
Officer | 43.35K | Stock Award(Grant) |
WARNER DOUGLAS J |
Officer | 25.00K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
25.79
+1.03% from price
SMA 20
27.98
-6.90% from price
SMA 50
29.63
-12.08% from price
SMA 100
31.87
-18.26% from price
SMA 200
29.77
-12.49% from price
EMA 12
26.61
-2.09% from price
EMA 26
27.98
-6.90% from price
EMA 50
29.29
-11.06% from price
RSI (14)
40.4
Neutral
MACD (12,26,9)
-1.37
Hist -0.06
ATR (14)
1.66
6.39% of price
Realised vol 30D
78.1%
Annualised
Bollinger upper
33.73
20, 2σ
Bollinger lower
22.23
20, 2σ
50 / 200 cross
Death
29.63 vs 29.77
Trend bias
Below 200
-12.49%
Risk profile
Beta vs SPY
0.60
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
78.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-36.8%
Peak to trough
Max drawdown 5Y
-83.2%
Peak to trough
ATR 14
1.66
6.39% of price
Beta (reported)
0.77
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.44
Call-heavy session
Put / call open interest
0.02
Positioning, not flow
Max pain
25.00
-4.0% from spot
ATM implied vol
162.9%
Nearest strike to spot
Skew (10% OTM)
-10.1%
Calls bid over puts
Call volume
142
Contracts, this expiry
Put volume
63
Contracts, this expiry
Heaviest call OI
40.00
2.31K contracts
Heaviest put OI
15.00
23 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
PR Newswire · 18d ago
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?
Insider Monkey · 53d ago
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
PR Newswire · 60d ago
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?
Simply Wall St. · 72d ago
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says
MT Newswires · 73d ago
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)
Insider Monkey · 82d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.